Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.98 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
3 Ultra-Cheap Dividend Stocks to Buy Right Now
Via The Motley Fool
1 Stock Down 43% That Looks Too Cheap to Ignore
Via The Motley Fool
Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S.... 
Via Benzinga
Topics Government World Trade
Milestone Merger Payment with Predictive Oncology to Advance AI-Driven Biomarker Discovery & Precision Medicine in Cancer & Beyond: Stock Symbol: RENB
$RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAILOS ANGELES - March 3, 2025 - PRLog -- Developing AI and Biotechnology Platforms for Early... 
Via PRLog
Topics Artificial Intelligence Intellectual Property
Most active S&P500 stocks in Monday's session
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
Zoetis (ZTS): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Zoetis’s shares (currently trading at $166) have posted a disappointing 9.6% loss, well below the S&P 500’s 7.6% gain. This was partly driven by its softer quarterly results... 
Via StockStory
Topics Stocks
2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now
Via The Motley Fool
From Losing $60K To Running a $100M Business: CEOs Share Their Biggest Lessons
 
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts. 
Via Benzinga
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Moderna is under pressure as two of its vaccines hit potential snags. 
Via Investor's Business Daily
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors. 
Via Stocktwits
Most active S&P500 stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Bill Gates Says 'Next Pandemic Can Emerge Anywhere' And The World Isn't Prepared: 'We Can't Afford To Get Caught Flat-Footed Again'
 
Via Benzinga
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Elanco (ELAN) Q4 Earnings Report Preview: What To Look For
Animal health company Elanco (NYSE:ELAN) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
Market Monitor February 24th
Wall Street Slumps Amid Consumer Worries and New Virus Concerns from China 
Via Chartmill
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy. 
Via Stocktwits
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations. 
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold Forever
Via The Motley Fool
3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.